Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-02-21
2006-02-21
Parkin, J. S. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07001736
ABSTRACT:
The present invention provides a method for the determining the appropriate therapy and/or prognosis for a patient diagnosed with a non-Alzheimer's disease (AD) neurological disease based upon the patient's apoE allele load. The invention also provides a method for the identification of human subjects with a non-AD neurological disease that are likely to respond in clinical trials that test pharmaceuticals useful in the treatment of neurological diseases.
REFERENCES:
patent: 5508167 (1996-04-01), Roses et al.
patent: 5935781 (1999-08-01), Poirier
patent: 2716894 (1995-09-01), None
patent: 94/09155 (1994-04-01), None
patent: 95/16791 (1995-06-01), None
patent: 95/29257 (1995-11-01), None
patent: 9603656 (1996-02-01), None
patent: WO 96 02670 (1996-02-01), None
patent: WO 96 03656 (1996-02-01), None
Farlow et al., 1996, “Apolipoprotein E. Genotype and Gender Influence Response to Tacrine Therapy”, Ann. N.Y. Acad. Sci. 802:101-110.
Timchenko et al., 1996, “Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues”, FASEB J. 10:1589-1597.
Salvatore et al., 1995, “Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease” Neurosci. Letters 199:95-98.
Brouillet et al., 1995, “Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates”, Proc. Natl. Acad. Sci. USA 92:7105-7109.
Morris, C. M., et al., 1996, “Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias”, J. Neural. Transm., 47:205-218.
Timchenko et al., 1996, “Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues”, FASEB J. 10:1589-1597.
Salvatore et al., 1995, “Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease” Neurosci. Letters 199:95-98.
Brouillet et al., 1995, “Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates”, Proc. Natl. Acad. Sci. USA 92:7105-7109.
Poirier, J., et al., 1995, “Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease”, Proc. Natl. Acad. Sci. USA 92(26):12260-12264.
Martin, J. B., and F. M. Longo,-1998, “Molecular diagnosis of neurologic disorders”, inHarrison's Principles of Internal Medicine, Fauci, A. S., et al., eds., McGraw-Hill, New York, pp. 2293-2307.
Mattila, P. M., et al., 1998, “Apolipoprotein E ε4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology”, Acta. Neuropathol. 96:417-420.
Rubinsztein, D. C., et al., 1994, “Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease”, Mol. Cell. Probes, 8:519-525.
Marder, K., et al., 1994, “The apolipoprotein ε4 allele in Parkinson's disease with and without dementia”, Neurol. 44:1330-1331.
Weatherby, S. J. M., et al., 2000, “No association between the APOE epsilon4 allele and outcome and susceptibility in primary progressive multiple sclerosis”, J. Neurol. Neurosurg. Psychiatry 68:532.
Whitehead, A. S., et al., 1996, “Frequency of the apolipoprotein E epsilon4 allele in a case-control study of early onset Parkinson's disease”, J. Neurol. Neurosurg. Psychiatry 61:347-351.
Hardy et al., Alzheimer's Disease Collaborative Group, “Apolipoprotein Genotype E and Alzheimer's Disease”, Lancet 342:737-738, 1993.
Bartus et al., “The Cholinergic Hypothesis of Geriatric Memory Dysfunction”, Science 217:408-417.
Bertrand et al., “Association of Apolipoprotein E Genotype with Brain Levels of Apolipoprotein E and Apolipoprotein J(clusterin) in Alzheimer's Disease”, Mol. Brain Res. 33:174-178, 1995.
Boyle et al., “Apolipoprotein E Associated with Astrocytic Glia of the Central Nervous System and With Non Myelinating Glia of the Peripheral Nervous System”, J. Clin. Invest. 76:1501-1513, 1985.
Brouillet et al., “Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates”, Proc. Natl. Acad. Sco. USA 92:7105-7109 (1995).
Corder et al., “Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families”, Science 261:921-923, 1993.
Farlow et al., “Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy”, Ann. N.Y. Acad. Sci. 802:101-110 (1996).
Goodrum, “Cholesterol Synthesis is Down-Regulated During Regeneration of Peripheral Nerve”, J. Neurochem 54:1709-1715, 1990.
Koo et al., “Obligatory Role of Cholesterol and Apolipoprotein E in the Formation of Large Cholesterol-Enriched and Receptor Active High Density Lipoproteins”, J. Biol. Chem 260:11934-11943, 1985.
Leblanc et al., “Regulation of Apolipoprotein E Gene Expression After Injury of the Rat Sciatic Nerve”, J. Neurosis. Res. 25:162-171, 1990.
Masliah et al., “Neurodegeneration in the Central Nervous System of apoE-Deficient Mice”, Exp. Neurol. 136:107-122, 1995.
Masliah et al., “Apolipoprotein E Role In Maintaining the Integrity of the Aging Central Nervous System in: Apolipoprotein E and Alzheimer's Disease”, Springer-Verlag, Heidelberg pp 59-73, 1996.
Nalbantoglu et al., “Predictive Value of Apolipoprotein E Genotyping in Alzheimer's Disease . . . ”, Ann. Neurol. 36:889-895, 1994.
Noguchi et al., “Apolipoprotein E and Alzheimer's Disease”, Lancet (letter) 342:737, 1993.
Payami et al., “Apolipoprotein E and Alzheimer's Disease”, Lancet (letter) 342:738, 1993.
Poirier et al., “Apolipoprotein E Allele As a Predictor of Cholinergic Deficits and Treatment Outcome in Alzheimer's Disease”, Proc. Natl. Acad. Act. 92:12260-12264, 1995.
Poirier et al., “Cholesterol Synthesis and Lipoprotein Reuptake During Synaptic Remodelling in Hippocampus in Adult Rats”, Neuroscience 55:81-90, 1993.
Poirier et al., “Apolipoprotein E Polymorphism and Alzheimer's Disease”, Lancet 342:697-699, 1993.
Poirier et al., “Apolipoprotein E, Cholinergic Integrity and Synaptic Plasticity in Alzheimer's Disease in: Apolipoprotein E and Alzheimer's Disease”, Springer-Verlag, Heidelberg pp 22-32, 1996.
Poirier et al., “Astrocytic Apolipoprotein E mRNA and GFAP mRNA in Hippocampus After Entorhinal Cortex Lesioning”, Mol. Brain Res. 11:97-106, 1991.
Poirier et al., “Cloning of Hippocampal poly(A) RNA Sequences that Increase After Emtorhinal Cortex Lesion in Adult Rat”, Mol. Brain Red. 9:191-195, 1991.
Reed et al., “Lower Cognitive Performance in Normal Older Adult Male Twins Carrying the Apolipoprotein E Epsilon 4 Allele”, Arch Neurol. 51:1189-1192, 1994.
Rothe et al., “Uptake of Endoneurial Lipoprotein Into Schwann Cells and Sensory Neurons is Mediated by Low Density Lipoprotein Receptors and Stimulated After Axonal Injury”, J. Neurochem. 57:2016-2025, 1991.
Salvatore et al., “Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease”, Neurosci. Letters 199:95-98 (1995).
Schellenberg et al., “Genetic Analysis of Familial Alzheimer's Disease”, Neurobiol. Aging 17:149, 1996.
Sorbi et al., “ApoE as a diagnostic factor for post-traumatic coma”, Nature Medicine 1(9):852 (1995).
Timchenko et al., “Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues”, FASEB J. 10:1589-1597 (1996).
Nicoll et al., “Apolipoprotein E ε4 Allele is Associated with Deposition of Amyloid β-Protein Following Head Injury,”Nature Medicine2:135-137, 1995.
Roses and Saunders, “Head Injury, Amyloid β and Alzheimer's Disease,”Nature Medicine7:603-604, 1995.
Sorbi et al., “ApoE as a Prognostic F
Bieker-Brady Kristina
Clark & Elbing LLP
Parkin J. S.
Poirier Judés
LandOfFree
Pharmacogenetic methods for use in the treatment of nervous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmacogenetic methods for use in the treatment of nervous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacogenetic methods for use in the treatment of nervous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3647327